Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
Status:
Completed
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
The aim of the study is to examine whether determining treatment strategies based upon
Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome
in patients with psychosis.
The investigators predict that prospectively testing CYP2D6 genotype and using this
information to treat psychotic patients with risperidone will improve clinical outcomes.
Specifically, CYP2D6 poor metabolizers who are treated with low dose and slow titration of
risperidone will do better than those who are treated with usual dose and titration approach
in terms of rates of side effects and clinical improvement.